5 days ago
1
The United States Food and Drug Administration (U.S. FDA) has issued an Official Action Indicated (OAI) classification to Aurobindo Pharma subsidiary Eugia Pharma Specialities’ formulation manufacturing installation adjacent Hyderabad.
OAI is 1 of the 3 classifications the regulator categorises station its inspection and it means regulatory and/or administrative actions are recommended.
The U.S. FDA had inspected the installation of Eugia Pharma’s, successful Kolthur colony of Ranga Reddy district, from February 16-27 and issued 4 observations. Aurobindo Pharma said “the FDA has present determined the inspection classification of this installation is authoritative enactment indicated (OAI).”
The institution is committed to maintaining the highest prime manufacturing standards astatine each of its facilities crossed the globe, it said successful a filing connected Sunday, May 24, 2026.
The different 2 classifications the U.S. FDA issues, aft inspections, are No Action Indicated (NAI) conveying that nary objectionable conditions oregon practices were recovered during inspection; and Voluntary Action Indicated (VAI) meaning objectionable conditions oregon practices were found, but it is not prepared to instrumentality oregon urge immoderate administrative oregon regulatory action.
